COST-EFFECTIVENESS OF A SINGLE-INHALER TRIPLE THERAPY VS A DUAL BRONCHODILATOR FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA

被引：0

作者：

Schembri, S. ^{[1
]}

Schroeder, M. ^{[2
]}

Shah, D. ^{[3
]}

Martin, A. ^{[4
]}

Ndirangu, A. ^{[3
]}

Risebrough, N. ^{[3
]}

Thrasis, A. ^{[5
]}

Bremner, P. ^{[6
]}

Haberl, M. ^{[5
]}

Ismaila, A. ^{[7
]}

机构：

[1] Canberra Hosp, Dept Resp & Sleep Med, Garran, ACT, Australia

[2] GlaxoSmithKline, Value Evidence & Outcomes, Brentford, England

[3] ICON Hlth Econ, Dublin, Ireland

[4] GlaxoSmithKline, Value Evidence Analyt, Brentford, England

[5] GlaxoSmithKline, Reimbursement & Pricing, Brentford, England

[6] Univ Notre Dame, Sch Med, Resp Med, Notre Dame, IN 46556 USA

[7] GlaxoSmithKline, Value Evidence & Outcomes, Brentford, England

来源：

RESPIROLOGY | 2020年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

TP 071

引用

页码：145 / 145

页数：1

共 50 条

[21] COST-EFFECTIVENESS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS TIOTROPIUM MONOTHERAPY IN PATIENTS WITH COPD IN THE UK
Martin, A.
Shah, D.
Shukla, S.
Kendall, R.
Risebrough, N. A.
Compton, C.
Ismaila, A.
VALUE IN HEALTH, 2022, 25 (01) : S40 - S40
[22] Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease
Benjamin Wu
David Mannino
George Mu
Marjorie Stiegler
Michael Bogart
Pulmonary Therapy, 2022, 8 : 195 - 208
[23] Comparative Effectiveness and Safety of Single-Inhaler Triple Therapy for COPD
Feldman, William B.
Suissa, Samy
Kesselheim, Aaron
Avorn, Jerry
Russo, Massimiliano
Schneeweiss, Sebastian
Wang, Shirley V.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 683 - 684
[24] Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease
Wu, Benjamin
Mannino, David
Mu, George
Stiegler, Marjorie
Bogart, Michael
PULMONARY THERAPY, 2022, 8 (02) : 195 - 208
[25] COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY VERSUS A DUAL INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN
Benjamin, N.
Huerta, A.
Biswas, C.
Schroeder, M.
Whalen, J.
Izquierdo Alonso, J. L.
Soler Cataluna, J. J.
Riesco Miranda, J. A.
Martin, A.
Atienza, L.
Ismaila, A.
VALUE IN HEALTH, 2018, 21 : S3 - S3
[26] COST-EFFECTIVENESS OF A SINGLE INHALER TRIPLE THERAPY VS A DUAL INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (ICS/LABA) FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UNITED KINGDOM (UK)
Fenwick, E.
Martin, A. A.
Schroeder, M.
Vetrini, D.
Mealing, S.
Risebrough, N.
Solanke, O.
Ismaila, A.
VALUE IN HEALTH, 2018, 21 : S234 - S234
[27] Triple therapy vs. dual bronchodilator therapy for chronic pulmonary disease: Is it worth the cost?
Horita, Nobuyuki
Kaneko, Takeshi
RESPIRATORY INVESTIGATION, 2015, 53 (04) : 173 - 175
[28] The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
Dobler, Claudia C.
BREATHE, 2018, 14 (04) : 333 - 335
[29] Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
Lipson, David A.
Barnhart, Frank
Brealey, Noushin
Brooks, Jean
Criner, Gerard J.
Day, Nicola C.
Dransfield, Mark T.
Halpin, David M. G.
Han, MeiLan K.
Jones, C. Elaine
Kilbride, Sally
Lange, Peter
Lomas, David A.
Martinez, Fernando J.
Singh, Dave
Tabberer, Maggie
Wise, Robert A.
Pascoe, Steven J.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (18): : 1671 - 1680
[30] Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany-The TriOptimize Study
Gessner, Christian
Trinkmann, Frederik
Javan, Sanaz Bahari
Hoevelmann, Raimund
Bogoevska, Valentina
Georges, George
Nudo, Elena
Criee, Carl-Peter
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 3019 - 3031

← 1 2 3 4 5 →